New migraine drug tested on 3,000 people in Real-Life settings
NCT ID NCT06439628
First seen Feb 06, 2026 · Last updated May 12, 2026 · Updated 17 times
Summary
This study looks at how well Rimegepant works for treating migraine attacks in everyday life. About 3,000 adults with migraine will take the drug as needed and report their pain levels, relief timing, and satisfaction. Researchers will also track long-term effects on migraine frequency and quality of life over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhenjiang, China
Conditions
Explore the condition pages connected to this study.